Second-line therapy for advanced NSCLC

Oncologist

Volumn 18, Issue 8, 2013, Pages 947-953

  Weiss, Jared M ^a   Stinchcombe, Thomas E ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Docetaxel; Gefitinib; Non small cell lung cancer; Pemetrexed

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; BMS 936559; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GANETESPIB; GEFITINIB; IFOSFAMIDE; MICROTUBULE ASSOCIATED PROTEIN 4; MITOGEN ACTIVATED PROTEIN KINASE; NAVELBINE; ONARTUZUMAB; PEMETREXED; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; SELUMETINIB; UNCLASSIFIED DRUG;

ANEMIA; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CYTOTOXICITY; DISEASE CONTROL; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FUSION GENE; GENE MUTATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG NON SMALL CELL CANCER; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA;

DOCETAXEL; ERLOTINIB, EGFR MUTATION, KRAS MUTATION, EML4/ALK REARRANGEMENT, ROS1 REARRANGEMENT; GEFITINIB; MET AMPLIFICATION; NON-SMALL CELL LUNG CANCER; PEMETREXED;

CARCINOMA, NON-SMALL-CELL LUNG; GLUTAMATES; GUANINE; HUMANS; MUTATION; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS;

EID: 84883234036     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0096     Document Type: Article

References (56)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. Azzoli CG, Baker S Jr. Temin S et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-smallcell lung cancer. J Clin Oncol 2009;27:6251-6266.
4. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
6. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The tax 320 nonsmall cell lung cancer study group J Clin Oncol 2000; 18:2354-2362.
7. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
8. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008;372:1809-1818.
9. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced nonsmall-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
10. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-smallcell lung cancer:Arandomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
11. D'Angelo SP, Pietanza MC, Johnson ML et al. Incidence of EGFR exon 19 deletions and l858r in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011;29: 2066-2070.
12. Kris MG, Kwiatkowski DJ, Iafrate AJ et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma:The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29 (suppl):CRA7506.
13. Takeuchi K, Choi YL, Soda M et al. Multiplex reverse transcription-pcr screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-6624.
14. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290:2149-2158.
15. Dancey J, Shepherd FA, Gralla RJ et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer 2004;43:183-194.
16. Di Maio M, Perrone F, Chiodini P et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007;25: 1377-1382.
17. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
18. Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Groupstudy br. 21. J Clin Oncol 2006;24:3831-3837.
19. Douillard JY, Shepherd FA, Hirsh V et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-752.
20. Fukuoka M, Yano S, Giaccone G et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (the IDEAL 1 trial) [corrected]. J Clin Oncol 2003;21:2237-2246.
21. Stinchcombe TE, Socinski MA. Gefitinib in advanced non-small cell lung cancer: Does it deserve a second chance? The Oncologist 2008;13:933-944.
22. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (IRESSA survival evaluation in lung cancer). Lancet 2005;366:1527-1537.
23. Vamvakas L, Kentepozidis NK, Karampeazis A et al. Pemetrexed (mta) compared with erlotinib (erl) in pretreated patients with advanced nonsmall cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. J Clin Oncol 2010;28 (suppl):7519a.
24. Ciuleanu T, Stelmakh L, Cicenas S et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, nonsmall-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012;13:300-308.
25. Garassino MCOM, Bettini A, Floriani I et al. Tailor: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (WT) EGFR. J Clin Oncol 2012;30 (suppl):LBA7501.
26. Zhu CQ, daCunha Santos G, Ding K et al. Role of kras and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study br. 21. J Clin Oncol 2008;26: 4268-4275.
27. Okano Y, Asami K, Fukuda M et al. Randomized phase III trial of erlotinib (e) versus docetaxel (d) as second-or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and erlotinib lung cancer trial (DELTA). J Clin Oncol 2013;31 (suppl): 8006a.
28. Lazzari C, Barni S, Aieta M et al. Randomized proteomic stratified phase III study of second-line erlotinib (e) versus chemotherapy (ct) in patients with inoperable non-small cell lung cancer (PROSE). J Clin Oncol 2013;31 (suppl):LBA8005.
29. Chaft JE, Oxnard GR, Sima CS et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design. Clin Cancer Res 2011; 17:6298-6303.
30. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
31. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784.
32. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
33. Herbst RS, Prager D, Hermann R et al. Tribute: A phase III trial of erlotinib hydrochloride (osi-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
34. Stinchcombe TE, Peterman AH, Lee CB et al. A randomizedphase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabineanderlotinib in elderly patients (age >/=70 years) with stage IIIb/IV non-small cell lung cancer. J Thorac Oncol 2011;6:1569-1577.
35. Heon S, Nishino M, Goldberg SB et al. Response to EGFR tyrosine kinase inhibitor (TKI) retreatment afteradrug-freeintervalin EGFR-mutantadvancednonsmall cell lung cancer (NSCLC) with acquired resistance. J Clin Oncol 2012;30 (suppl):7525a.
36. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
37. Weickhardt AJ, Burke JM, Gan G et al. Continuation of EGFR/alk inhibition after local therapy of oligoprogressive disease in EGFR mutant (MT) and ALK + non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30 (suppl): 7526a.
38. Yu HA, Drilon AEDC, Varghese AM et al. Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Clin Oncol 2012;30 (suppl):7527a.
39. Janjigian YY, Horn L, Groen HJM et al. Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors. Paper presented at: European Society of Medical Oncology; September 30, 2012; Viena, Austria.
40. Takeuchi K, Choi YL, Soda M et al. Multiplex reverse transcription-pcr screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-6624.
41. Shaw AT, Nakagawa K, Seto T et al. Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) (PROFILE 1007). Paper presented at: European Society of Medical Oncology;September30, 2012; Viena, Austria.
42. Camidge DR, Bang YJ, Kwak EL et al. Progression-free survival (PFS) from a phase I study of crizotinib (pf-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29:2501a.
43. Camidge DR, Kono SA, Lu X et al. Anaplastic lymphoma kinase gene rearrangements in nonsmall cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011;6:774-780.
44. Lee JO, Kim TM, Lee SH et al. Anaplastic lymphoma kinase translocation: A predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011;6:1474-1480.
45. Felip E, Barlesi F, Gandhi L et al. Phase II activity of the HSP90 inhibitor AUY922 in patients with ALKrearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer (NSCLC). Paper presented at: European Society of Medical Oncology; September 29, 2012; Viena, Austria.)
46. Mehra R, Camidge DR, Sharma S et al. First-inhuman phase I study of the ALK inhibitor LDK378 in advancedsolid tumors. J Clin Oncol 2012;30 (suppl): 3007a.
47. Sequist LV, Gettinger S, Senzer NN et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-smallcell lung cancer. J Clin Oncol 2010;28:4953-4960.
48. Wong K, Goldman JW, Paschold EH et al. An open-label phase II study of the HSP90 inhibitor ganetespib (sta-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29 (suppl):7500a.
49. Kris MG, Kwiatkowski DJ, Iafrate AJ et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma:The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011;29 (suppl):CRA7506.
50. Janne PA, Shaw AT, Pereira JR et al. Phase II double-blind, randomized study of selumetinib (sel) plus docetaxel (doc) versus doc plus placebo as second-line treatment for advanced kras mutant nonsmall cell lung cancer (NSCLC). J Clin Oncol 2012;30 (suppl):7503a.
51. Ramalingam SS, Goss GD, Manegold C Sr et al. The GALAXY Trial (NCT 01348126): A randomized IIB/III study of ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone as second line therapy in patients with stage IIIB or IV NSCLC. Paper presented at: European Society of Medical Oncology;September29, 2012; Viena, Austria.
52. Cappuzzo F, Marchetti A, Skokan M et al. Increased met gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-1674.
53. Spigel DR, Ramlau R, Daniel DB et al. Final efficacy results from OAM4558g, arandomized phase II study evaluating metmab or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011;29 (suppl):7505a.
54. Spigel David R. MJE, Tony MOK, Kenneth John O'Byrne, Luis Paz-Ares, Wei Yu, Karen Rittweger, Holger C. Thurm. The metlung study:Arandomized, double-blind, phase iii study of onartuzumab (metmab) plus erlotinib versus placebo plus erlotinib in patients with advanced, met-positive non-small cell lung cancer (nsclc). J Clin Oncol 30, 2012 (suppl; abstr TPS7616).
55. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-pd-l1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.
56. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-pd-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.